An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) announced that President and COO Michael Benkowitz will provide a business overview at the Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, from 9:10 a.m. to 9:40 a.m. EST. The session will be accessible via a live webcast on the company's website and an archived version will be available for 90 days post-event. United Therapeutics, as a public benefit corporation, focuses on innovative pharmaceutical therapies and technologies for transplantable organs, aiming to meet the medical needs of patients.
Positive
None.
Negative
None.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session at the Cowen 43rd Annual Health Care Conference in Boston.
The session will take place on Tuesday, March 7, 2023, from 9:10 a.m. to 9:40 a.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed at the same location for 90 days.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
You can learn more about what it means to be a PBC here: unither.com/PBC.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of February 28, 2023 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
